• About
    • Who We Are
    • Leadership Team
    • Board of Directors
    • Clinical and Scientific Advisors
    • Contact
  • Science
    • Immune Continuum
    • CCR4 in Cancer
    • CCR4 in Inflammation
    • HPK1
    • Publications
  • Pipeline
    • Snapshot
    • FLX475
    • RPT193
    • HPK1
    • Discovery Programs
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Email Alerts
    • Investor Contact
    • Investor FAQs
  • Careers
    • Culture
    • Benefits
    • Open Positions

PRESS RELEASES

Year
November 19 | 2018
FLX Bio to Present at Evercore ISI HealthCONx Conference
November 08 | 2018
FLX Bio Highlights Phase 1 Data for FLX475 at SITC 2018
November 05 | 2018
FLX Bio Announces Clinical Trial Collaboration Agreement With Merck for Ongoing Phase 1/2 Study of FLX475
October 03 | 2018
FierceBiotech Names FLX Bio as One of its “Fierce 15” Biotech Companies of 2018
September 27 | 2018
FLX Bio Announces First Patient Dosed With FLX475, a Best-in-Class CCR4 Inhibitor for the Treatment of Multiple Cancers
August 08 | 2018
FLX Bio to Present at the 2018 Wedbush PacGrow Healthcare Conference
June 01 | 2018
FLX Bio to Present at the Jefferies Global Healthcare Conference
April 12 | 2018
FLX Bio to Highlight New Preclinical Data from CCR4 and USP7 Programs at the American Academy for Cancer Research Annual Meeting
February 12 | 2018
FLX Bio to Present at RBC Capital Markets 2018 Global Healthcare Conference
February 05 | 2018
FLX Bio Adds Distinguished Biopharma Industry Leader Michael Giordano, M.D., to Board of Directors
January 03 | 2018
FLX Bio Appoints Dirk G. Brockstedt, Ph.D., as Senior Vice President of Biology
Contact Us
+1.650.489.9000
inquiries@rapt.com
  • Home
  • About
  • Science
  • Pipeline
  • Investors & Media
  • Careers
  • Terms Of Use
  • Privacy Policy

RAPT Therapeutics
561 Eccles Avenue
South San Francisco, CA 94080
Tel: +1 650 489 9000
Email: inquiries@rapt.com

RAPT Therapeutics, formerly known as FLX Bio.

© 2023 RAPT Therapeutics. All right reserved.